国际检验医学杂志
國際檢驗醫學雜誌
국제검험의학잡지
INTERNATIONAL JOURNAL OF LABORATORY MEDICINE
2010年
1期
8-10
,共3页
宗明%范列英%杨蔺%杨达人%吕红根%叶勤
宗明%範列英%楊藺%楊達人%呂紅根%葉勤
종명%범렬영%양린%양체인%려홍근%협근
葡萄糖-6-磷酸异构酶%抗原抗体复合物%关节炎,类风湿
葡萄糖-6-燐痠異構酶%抗原抗體複閤物%關節炎,類風濕
포도당-6-린산이구매%항원항체복합물%관절염,류풍습
Glucose-6-phosphate isomerase%Antigen-Antibody complex%Arthritis,rheumatoid
目的 建立葡萄糖-6-磷酸异构酶(G6PI)免疫复合物测定方法,初步探讨其与类风湿关节炎(RA)发病机制的关系及其对RA辅助诊断、病情监测的作用.方法 建立Clq抗体捕获ELISA方法,并对311例m清标本(RA患者176例、其他免疫疾病患者35例和健康体榆者100例)和44例关节液标本(RA患者33例、非RA关节疾病患者11例)中的G6PI/G6PI抗体/Clq免疫复合物水平进行检测.结果 以波长450 nm吸光度值(A_(450nm))表示复合物含量,176例RA患者血清中G6PI免疫复合物为0.918±0.507,显著高于其他免疫疾病对照组(0.746±0.399)和健康对照组(0.696±0.362),P<0.01;而两对照组间差异无统计学意义.RA活动组为1.045±0.529,显著高于非活动组(0.764±0.436),P<0.01.以健康对照组A_(450 nm)值建立正常参考区间,结果G6PI免疫复合物对RA诊断的敏感性和特异性分别为60.2%和67.4%,活动期RA的阳性率为74%,显著高于非活动期(43.7%).33例RA患者、11例其他关节疾病患者关节液中G6PI免疫复合物A_(450nm)分别为0.835±0.497和0.596±0.132,RA患者组显著高于其他关节病组,P<0.05.结论 RA患者血清和关节液G6PI免疫复合物含量增高,且增高程度与RA病情活动相关;G6PI免疫复合物可能在RA发病中起重要作用,且与疾病的活动性密切相关.
目的 建立葡萄糖-6-燐痠異構酶(G6PI)免疫複閤物測定方法,初步探討其與類風濕關節炎(RA)髮病機製的關繫及其對RA輔助診斷、病情鑑測的作用.方法 建立Clq抗體捕穫ELISA方法,併對311例m清標本(RA患者176例、其他免疫疾病患者35例和健康體榆者100例)和44例關節液標本(RA患者33例、非RA關節疾病患者11例)中的G6PI/G6PI抗體/Clq免疫複閤物水平進行檢測.結果 以波長450 nm吸光度值(A_(450nm))錶示複閤物含量,176例RA患者血清中G6PI免疫複閤物為0.918±0.507,顯著高于其他免疫疾病對照組(0.746±0.399)和健康對照組(0.696±0.362),P<0.01;而兩對照組間差異無統計學意義.RA活動組為1.045±0.529,顯著高于非活動組(0.764±0.436),P<0.01.以健康對照組A_(450 nm)值建立正常參攷區間,結果G6PI免疫複閤物對RA診斷的敏感性和特異性分彆為60.2%和67.4%,活動期RA的暘性率為74%,顯著高于非活動期(43.7%).33例RA患者、11例其他關節疾病患者關節液中G6PI免疫複閤物A_(450nm)分彆為0.835±0.497和0.596±0.132,RA患者組顯著高于其他關節病組,P<0.05.結論 RA患者血清和關節液G6PI免疫複閤物含量增高,且增高程度與RA病情活動相關;G6PI免疫複閤物可能在RA髮病中起重要作用,且與疾病的活動性密切相關.
목적 건립포도당-6-린산이구매(G6PI)면역복합물측정방법,초보탐토기여류풍습관절염(RA)발병궤제적관계급기대RA보조진단、병정감측적작용.방법 건립Clq항체포획ELISA방법,병대311례m청표본(RA환자176례、기타면역질병환자35례화건강체유자100례)화44례관절액표본(RA환자33례、비RA관절질병환자11례)중적G6PI/G6PI항체/Clq면역복합물수평진행검측.결과 이파장450 nm흡광도치(A_(450nm))표시복합물함량,176례RA환자혈청중G6PI면역복합물위0.918±0.507,현저고우기타면역질병대조조(0.746±0.399)화건강대조조(0.696±0.362),P<0.01;이량대조조간차이무통계학의의.RA활동조위1.045±0.529,현저고우비활동조(0.764±0.436),P<0.01.이건강대조조A_(450 nm)치건립정상삼고구간,결과G6PI면역복합물대RA진단적민감성화특이성분별위60.2%화67.4%,활동기RA적양성솔위74%,현저고우비활동기(43.7%).33례RA환자、11례기타관절질병환자관절액중G6PI면역복합물A_(450nm)분별위0.835±0.497화0.596±0.132,RA환자조현저고우기타관절병조,P<0.05.결론 RA환자혈청화관절액G6PI면역복합물함량증고,차증고정도여RA병정활동상관;G6PI면역복합물가능재RA발병중기중요작용,차여질병적활동성밀절상관.
Objective To establish a method to measure glucose-6-phophateisomerase(G6PI)-containing complex in serum and synovial fluid of the patients with rheumatoid arthritis(RA) by enzyme-linked immunosorbent assay(ELISA) and to study the mechanism of G6PI/G6PI Ab-containing complex in the development of RA. Methods A Clq antibody capture ELISA was devel-oped to detect Clq/G6PI/G6PI Ab-containing immune complexes. The level of G6PI/G6PI Ab-containing complex in serum of 176 patients with RA,35 with non-RA and 100 healthy donors and 44 synovial fluid of 33 patients with RA and 11 cases with non-RA were tested. Results The values of A450nm of the G6PI/G6PI Ab-containing complex in serum of 176 RA patients,35 non-RA pa-tients and 100 healthy controls were 0. 918±0. 507,0. 746±0. 399 and 0. 696±0. 362 respectively. The level of G6PI/G6PI Ab-containing complex in serum were abnormally increased in RA patients compared with healthy controls(P<0. 01). Among the RA patients, the active phase and the inactive phase were 1. 045±0. 529 and 0. 764±0. 436,respectively. Compared with RA inactive group, they were significantly higher in serum of active group(P<0.01). With the values of A_(450nm)of the healthy control subjects as confidence in terval, the value of the cut-off was 0. 755. The sensitivity and specificity of G6PI in the RA patients were 60. 2% and 67.4% respectively. The values of A_(450nm)of the G6PI/G6PI Ab-containing complex in synovia of 33 RA patients and 11 non-RA patients were 0. 835±0. 497 and 0. 596±0.132,respectively. In synovia, the level of G6PI/G6PI Ab-containing complex were significantly higher in RA patients than that in non-RA patients(P<(0.05). Conclusion The increased expression of G6PI/G6PI Ab-containing complex may play a pathological role in the development of RA,and it may be correlated with the activity of RA.